CDK4/6 Inhibitor Drugs Market Size & Share, by Drug Type (Palbociclib, Ribociclib, Abermaciclib, Dalpiciclib, Birociclib, Lerociclib, BPI 16350); Patient (PreMenopause, PostMenopausal); End User (Hospital, Clinics, Research Laboratories, Retail Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2533
  • Published Date: Jan 22, 2024
  • Report Format: PDF, PPT

 

  1. An Outline of the Global CDK 4/6 Inhibitor Drugs Market
    1. Market Definition
    2. Market Segmentation
    3. Industry Overview
  2. Assumptions & Abbreviations
  3. Research Methodology & Approach
    1. Research Process
    2. Primary Research
      1. Manufacturers
      2. Suppliers/Distributors
      3. End Users
    3. Secondary Research
    4. Market Size Estimation
  4. Summary of the Report for Key Decision Makers
  5. Forces of Market Constituents
    1. Factors/drivers impacting the growth of the market
    2. Market trends for better business practices
  6. Key Market Opportunities for Business Growth
  7. Major Roadblocks for the Market Growth
  8. Regulatory Landscape
  9. Industry Value Chain Analysis
  10. Recent Developments in the Market
  11. Impact of Covid-19
  12. Epidemiology
  13. Treatment Guidelines for Breast Cancer
  14. Unmet Needs
  15. Product Profiling
  16. Drug pricing and Reimbursements
  17. Comparative Drug Analysis
  18. Drug Pipeline Analysis
  19. Competitive Positioning
  20. Competitive Model: A Detailed Inside View for Investors
    1. Company Market Share (2022)
    2. Business Profile of Key Enterprise
      1. Pfizer Inc.
      2. Novartis
      3. Eli Lilly and Company
      4. Jiangshu Hengrui Pharmaceuticals Co. Ltd.
  21. Global CDK 4/6 Inhibitor Drugs Market Outlook
    1. Market Overview
    2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
    3. Year-on-Year (YoY) Growth Trend Analysis
    4. Global CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Drug Type
      1. Palbociclib, Market Value (USD Million) and CAGR, 2022-2035F
      2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
      3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
      4. Dalpiciclib, Market Value (USD Million), and CAGR, 2022-2035F
      5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
      6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
      7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
      8. Others, Market Value (USD Million), and CAGR, 2022-2035F
    5. Global CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Patient
      1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
      2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
      3. Others, Market Value (USD Million) and CAGR,  2022-2035F
    6. Global CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By End User
      1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
      2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
      3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
      4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
    7. Global CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By Geography
      1. North America, Market Value (USD Million), and CAGR, 2022-2035F
      2. Europe, Market Value (USD Million), and CAGR, 2022-2035F
      3. Asia Pacific, Market Value (USD Million), and CAGR, 2022-2035F
      4. Latin America, Market Value (USD Million), and CAGR, 2022-2035F
      5. Middle East & Africa, Market Value (USD Million), and CAGR, 2022-2035F
  22. North America CDK 4/6 Inhibitor Drugs Market Outlook
    1. Market Overview
    2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
    3. Year-on-Year (YoY) Growth Trend Analysis
    4. North America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Drug Type
      1. Palbociclib, Market Value (USD Million), and CAGR, 2022-2035F
      2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
      3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
      4. Dalpiciclib , Market Value (USD Million), and CAGR, 2022-2035F
      5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
      6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
      7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
      8. Others, Market Value (USD Million), and CAGR, 2022-2035F
    5. North America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Patient
      1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
      2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
      3. Others, Market Value (USD Million) and CAGR,  2022-2035F
    6. North America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By End User
      1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
      2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
      3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
      4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
    7. North America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By Country
      1. US, Market Value (USD Million), and CAGR, 2022-2035F
      2. Canada, Market Value (USD Million), and CAGR, 2022-2035F
  23. Europe CDK 4/6 Inhibitor Drugs Market Outlook
    1. Market Overview
    2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
    3. Year-on-Year (YoY) Growth Trend Analysis
    4. Europe CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Drug Type
      1. Palbociclib, Market Value (USD Million), and CAGR, 2022-2035F
      2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
      3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
      4. Dalpiciclib , Market Value (USD Million), and CAGR, 2022-2035F
      5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
      6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
      7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
      8. Others, Market Value (USD Million), and CAGR, 2022-203
    5. Europe CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Patient
      1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
      2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
      3. Others, Market Value (USD Million) and CAGR,  2022-2035F
    6. Europe CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By End-User
      1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
      2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
      3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
      4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
    7. Europe CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By Country
      1. UK, Market Value (USD Million), and CAGR, 2022-2035F
      2. Germany, Market Value (USD Million), and CAGR, 2022-2035F
      3. Italy, Market Value (USD Million), and CAGR, 2022-2035F
      4. France, Market Value (USD Million), and CAGR, 2022-2035F
      5. Spain, Market Value (USD Million), and CAGR, 2022-2035F
      6. Russia, Market Value (USD Million), and CAGR, 2022-2035F
      7. Netherlands, Market Value (USD Million), and CAGR, 2022-2035F
      8. Rest of Europe, Market Value (USD Million), and CAGR, 2022-2035F
  24. Asia Pacific CDK 4/6 Inhibitor Drugs Market Outlook
    1. Market Overview
    2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
    3. Year-on-Year (YoY) Growth Trend Analysis
    4. Asia Pacific CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Drug Type
      1. Palbociclib, Market Value (USD Million), and CAGR, 2022-2035F
      2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
      3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
      4. Dalpiciclib , Market Value (USD Million), and CAGR, 2022-2035F
      5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
      6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
      7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
      8. Others, Market Value (USD Million), and CAGR, 2022-203
    5. Asia Pacific CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Patient
      1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
      2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
      3. Others, Market Value (USD Million) and CAGR,  2022-2035F
    6. Asia Pacific CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By End-User
      1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
      2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
      3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
      4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
    7. Asia Pacific CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By Country
      1. China, Market Value (USD Million), and CAGR, 2022-2035F
      2. India, Market Value (USD Million), and CAGR, 2022-2035F
      3. Japan, Market Value (USD Million), and CAGR, 2022-2035F
      4. South Korea, Market Value (USD Million), and CAGR, 2022-2035F
      5. Singapore, Market Value (USD Million), and CAGR, 2022-2035F
      6. Australia, Market Value (USD Million), and CAGR, 2022-2035F
      7. Rest of Asia-Pacific, Market Value (USD Million), and CAGR, 2022-2035F
  25. Latin America CDK 4/6 Inhibitor Drugs Market Outlook
    1. Market Overview
    2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
    3. Year-on-Year (YoY) Growth Trend Analysis
    4. Latin America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Drug Type
      1. Palbociclib, Market Value (USD Million), and CAGR, 2022-2035F
      2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
      3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
      4. Dalpiciclib , Market Value (USD Million), and CAGR, 2022-2035F
      5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
      6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
      7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
      8. Others, Market Value (USD Million), and CAGR, 2022-203
    5. Latin America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Patient
      1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
      2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
      3. Others, Market Value (USD Million) and CAGR,  2022-2035F
    6. Latin America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By End-User
      1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
      2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
      3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
      4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
    7. Latin America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By Country
      1. Brazil, Market Value (USD Million), and CAGR, 2022-2035F
      2. Mexico, Market Value (USD Million), and CAGR, 2022-2035F
      3. Argentina, Market Value (USD Million), and CAGR, 2022-2035F
      4. Rest of Latin America, Market Value (USD Million), and CAGR, 2022-2035F
  26. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Outlook
    1. Market Overview
    2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
    3. Year-on-Year (YoY) Growth Trend Analysis
    4. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Drug Type
      1. Palbociclib, Market Value (USD Million), and CAGR, 2022-2035F
      2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
      3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
      4. Dalpiciclib , Market Value (USD Million), and CAGR, 2022-2035F
      5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
      6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
      7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
      8. Others, Market Value (USD Million), and CAGR, 2022-203
    5. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035, By Patient
      1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
      2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
      3. Others, Market Value (USD Million) and CAGR,  2022-2035F
    6. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035), By End-User
      1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
      2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
      3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
      4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
    7. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035) , By Country
      1. GCC, Market Value (USD Million), and CAGR, 2022-2035F
      2. Israel, Market Value (USD Million), and CAGR, 2022-2035F
      3. South Africa, Market Value (USD Million), and CAGR, 2022-2035F
      4. Rest of Middle East & Africa, Market Value (USD Million), and CAGR, 2022-2035F

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

CDK4/6 Inhibitor Drugs Market size is estimated to cross USD 66.63 Billion by the end of 2035, expanding around 16.78% CAGR during the forecast period i.e., 2023-2035. In the year 2022, the industry size of CDK4/6 inhibitor drugs was over USD 9.03 Billion. According to Breastcancer.org, breast cancer is the most common cancer in the world, accounting for 12.5% of new cancer cases worldwide each year. The increasing prevalence of breast cancer is a major driver of the CDK-4/6 inhibitor market. CDK4/6 inhibitors are effective in treating hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer, making them a valuable treatment option. As the incidence of breast cancer continues to increase worldwide, the demand for targeted and effective treatments such as CDK-4/6 inhibitors is increasing, contributing to market expansion.

As health spending increases, funding for research and development activities typically increases proportionately. Investment in innovative cancer treatments, coupled with increasing awareness of the effectiveness of these inhibitors, is contributing to their acceptance and market growth. Financial commitment to medical infrastructure and research will further accelerate the development and access of CDK4/6 inhibitors to cancer patients. The global CDK-4/6 inhibitors market is expected to witness strong growth during the forecast period. This is because medical costs per person are high.


CDK 46 Inhibitor Drugs Market overview
Get more information on this report: Request Free Sample PDF

CDK4/6 Inhibitor Drugs Sector: Growth Driver and Challenges

Growth Driver

  • Increasing Advancement in Drug Development - Drug treatment with CDK-4/6 inhibitors has proven to be the most promising advance in breast cancer treatment. Advances in pharmaceutical research and development highlight the exciting potential of CDK-4/6 inhibitors for the future of breast cancer treatment. Drug treatment with CDK4/6 inhibitors has been accepted in many countries due to its therapeutic efficacy compared to conventional breast cancer treatment. Increased number of drug treatments using CDK4/6 inhibitors in various stages of clinical trials and increased approval of inhibitory drug therapies by the FDA, leading to acceptance of new and advanced technologies in the field of breast cancer treatment. Now it looks like this. For example, on April 15, 2021, G1 Therapeutics began clinical trials for its CDK-4/6 inhibitor, trilaciclib. This drug is typically used in patients receiving gemcitabine and carboplatin for metastatic triple-negative breast cancer
  • Introduction of Targeted Therapies for the Treatment of Breast Cancer - In some targeted treatments, antibodies are administered that imitate the antibody resulting from natural human immune systems. Another name for these types of targeted therapy is immune targeting therapies. Breast cancer cells may overexpress specific receptors that, when activated, may cause downstream signaling to occur, leading to the activation of genes involved in cancer cell proliferation, growth, survival, migration, angiogenesis, and other critical cell cycle pathways.

Challenges

  • Side Effects of CDK4/6 Inhibitor Drug - The market for CDK4/6 inhibitor drugs is being held back by side effects associated with the treatment of CDK4/6 inhibitors. Abemaciclib: It causes various side effects such as diarrhea, low white blood cell counts, low red blood cell counts, blood clots, nausea: abdominal pain, fatigue, and vomiting. It can cause liver problems in a few cases. Before and during treatment, liver function checks are performed. In severe cases, it can cause lung inflammation, which can be fatal. Therefore, the side effects are expected to hinder market growth in the forthcoming period.
  • Limited Access to Advanced Healthcare is Predicted to Hamper the Market in the Forecast Period
  • Safety Concerns and Adverse Effects are Expected to Pose Limitations on the Market Expansion in the Upcoming Future.

CDK4/6 Inhibitor Drugs Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

16.78%

Base Year Market Size (2022)

USD 9.03 Billion

Forecast Year Market Size (2035)

USD 66.63 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

CDK4/6 Inhibitor Drugs Segmentation

End User (Hospital, Clinics, Research Laboratories, Retail Pharmacies)

In terms end user segmentation, the hospital segment in the CDK4/6 inhibitor drugs market is anticipated to surpass USD 38.18 billion by the end of 2035. As the incidence of breast cancer increases, hospitals hold the highest market share. In the case of cancer, we have a higher influx of patients than other medical institutions because we have cutting-edge treatment technology. Therefore, the demand for this drug is highest in the hospital end-use sector. Additionally, intensified efforts by governments to build a strong healthcare framework in hospitals across the countries is also expected to boost the market. Additionally, the increasing number of surgical hospitals with single specialty expertise is also contributing to the market growth.

Patient (PreMenopause, PostMenopausal)

CDK4/6 inhibitor drugs market size from the post-menopausal segment is set to cross USD 56.20 billion by the end of 2035. The majority of breast cancers in postmenopausal women are hormonal receptor-positive, and breast cancer is most common in these women. Women's breast fat cells tend to produce increasing levels of the enzyme aromatase as they become older. The enzyme aromatase promotes the synthesis of estrogen. Consequently, as women age, their breasts contain an increased quantity of oestrogen. Postmenopausal women's breast cancer growth and expansion are both influenced by this locally generated oestrogen. Palbociclib is used in conjunction with an aromatase inhibitor to treat postmenopausal women and men with hormone-receptor-positive, HER2-negative, advanced-stage or metastatic breast cancer that has not previously received hormonal therapy.

Our in-depth analysis of the global CDK4/6 inhibitor drugs market includes the following segments:

          Drug Type

  • Palbociclib
  • Ribociclib
  • Abermaciclib
  • Dalpiciclib
  • Birociclib
  • Lerociclib
  • BPI 16350

          Patient

  • Pre menopause
  • Post menopausal

          End User

  • Hospital
  • Clinics
  • Research Laboratories
  • Retail Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

CDK4/6 Inhibitor Drugs Industry - Regional Synopsis

North American Market Forecasts

The CDK4/6 inhibitor drugs market in the North America region is estimated to reach USD 45.96 billion by the end of the forecast period. Increasing number of clinical trials in the region is also driving market growth. The NCI-sponsored TAILORx clinical trial focused on patients with ER-positive, node-negative breast cancer and found that a test that looks at the expression of certain genes can predict which women can safely avoid chemotherapy. Other studies, such as RxPONDER, have found that some postmenopausal women with HER-2-negative, HR-positive breast cancer that has spread to multiple lymph nodes and has a low risk of recurrence do not benefit from chemotherapy. As a result, the demand for targeted therapies has increased significantly in the United States.

European Market Statistics

The CDK4/6 inhibitor drugs market in the Europe region is anticipated to grow significantly by registering a growth of USD 10.76 billion by the end of 2035. The European CDK-4/6 inhibitors market is growing significantly due to increasing government initiatives in major European countries such as the UK, Germany, Spain, and France. Additionally, the increasing prevalence of breast cancer has increased the use of advanced treatments and drugs, which is also one of the key factors driving the growth of the CDK-4/6 inhibitors market. Breast cancer accounts for 13.3% of all new cancer cases and is estimated to affect 1 in 11 of 74-year-old women in the EU.

Research Nester
CDK 46 Inhibitor Drugs Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the CDK4/6 Inhibitor Drugs Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • Eli Lilly and Company
    • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    • AstraZeneca plc
    • Celltrion, Inc
    • Merck & Co., Inc.
    • Halozyme Inc.
    • Sanofi
    • NATCO Pharma Limited

In-the-news

In The News

  • In April 2021, Pfizer announced the acquisition of Amplyx Pharmaceuticals Inc., which is a privately held company dedicated to discovering medicines for severe and sometimes fatal illnesses affecting people with weakened immune systems.
  • In 2023, Novartis announced improved invasive survival assessment results from the pivotal Phase 3 NATALEE study, with a median follow-up of 33.3 months and 78.3% of patients completing Kiscal therapy. These results confirm the benefit observed in a previous interim analysis in patients with HR+/HER2- early stages II and III  breast cancer who received adjuvant Kisqari and nonsteroidal aromatase inhibitors. Patients had a 25.1% increased chance of malignant recurrence compared with typical endocrine therapy. Comparison of therapy (ET) and ET alone.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2533
  • Published Date: Jan 22, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing cases of breast cancer and increasing advancement in drug development are some of the major factors anticipated to drive the growth of the CDK4/6 Inhibitor Drugs market.

The market is anticipated to attain a CAGR of ~16.78% over the forecast period, i.e., 2023-2035.

The major players in the market are of Novartis AG, Eli Lilly and Company, Jiangsu Hengrui Pharmaceuticals Co., Ltd., AstraZeneca plc, Celltrion, Inc, Merck & Co., Inc., Halozyme Inc., and others.

The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
CDK4/6 Inhibitor Drugs Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying